Ipilimumab
Top View
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Antibody Drug Nomenclature: -Umab -Zumab -Ximab
- Efficacy and Safety of Infliximab for Steroid‑Resistant Immune‑Related Adverse Events: a Retrospective Study
- YERVOY (Ipilimumab) Injection Is Available As Follows
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- Tocilizumab Intravenous – (M0004)
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Nivolumab/Ipilimumab Combination Therapy for Renal Cell Carcinoma (RCC) an HCP Tool from the Immuno-Oncology Essentials Initiative
- CLINICAL the Value of Specialty Pharmaceuticals– a Systematic Review
- Ipilimumab Therapy in Patients with Advanced Melanoma and Preexisting Autoimmune Disorders
- New Clinical Rx Forum Sept Oct 2017.Pub
- Concurrent Ipilimumab and CMV Colitis Refractory to Oral Steroids Andrew Perry, MD,A Jonathan Walter, MD,A Stephen Olsen, MD,B and George Ansstas, Mdc
- Infliximab-Refractory Checkpoint Colitis
- Nivolumab/Ipilimumab Combination Therapy for Melanoma: a Nursing Tool from the Melanoma Nursing Initiative (MNI)
- Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Rik J
- June 2011 Medicaid Bulletin
- (MRONJ): Late Onset 3 Years After Ipilimumab Endovenous Administration with a Possible Role of Target Therapy
- Vedolizumab Treatment for Immune Checkpoint Inhibitor-Induced Enterocolitis